Guoshu Yin

Multiorgan metabolic reprogramming induced by chiglitazar in a letrozole-induced PMOS mouse model: Insights from integrated omics analyses

BACKGROUND: Polyendocrine metabolic ovarian syndrome (PMOS), formerly named polycystic ovary syndrome (PCOS), is a common endocrine-metabolic disorder with limited treatments. Chiglitazar, a novel pan-PPAR agonist, shows multitarget potential, but its systemic mechanisms in PMOS...